Nodular Goiter
Return to Library
|
Free Nodular Goiter Articles |
|
|
|
|
New thyroid cancer data have been reported by researchers at Shanghai Jiao Tong University
2009 JUN 15 - (NewsRx.com) -- According to recent research from Shanghai, People's Republic of China, "The BRAF mutation V600E (BRAF(V600E)) is the most common genetic alteration in papillary thyroid carcinoma (PTC), while overexpression of X-linked inhibitor of apoptosis (XIAP) has been found in various tumors. Both of these events are implicated in carcinogenesis, tumor progression, recurrence, etc." "There are few reports, however, of the BRAF V600E mutation and XIAP overexpression in PTC patients. The aim of this study was to investigate the frequency of the BRAF V600E mutation in PTC and its relationship to clinicopathological parameters and the expression of XIAP. Genomic DNA was extracted from 123 paraffin-embedded PTC tumor tissue samples and amplified for analysis of the V600E mutation in exon 15 of the BRAF gene by polymerase chain reaction. XIAP expression was examined by immunohistochemical methods in 46 PTCs, 18 benign nodular goiters, and 10 Hashimoto's thyroiditis samples. The BRAF V600E mutation was found in 34.1% of PTC, and was especially prevalent in the classic type. BRAF V600E was significantly correlated with younger age at diagnosis (p=0.026), tumor size (p=0.009), and histological variants (p=0.024). There was a trend towards association with extrathyroidal invasion (p=0.067). By logistic regression analysis, a significant relationship was found between tumor size and the BRAF V600E mutation (p=0.03). XIAP was expressed in 82.6% of PTCs, which was a higher percentage than observed in the group of benign thyroid disorders (35.7%, p<0.001). Neither the intensity (p=0.611) nor the extent (p=0.723) of XIAP staining was correlated with the presence of BRAF V600E in PTC patients. These data indicate that BRAF V600E is associated some of the aggressive clinicopathological features of PTC including younger age at diagnosis, larger tumor size, and classic histological type, as well as also extrathyroidal invasion. XIAP-positive staining was more prevalent in PTCs than in the benign thyroid disorders," wrote L.Q. Gu and colleagues, Shanghai Jiao Tong University. The researchers concluded: "Although BRAF V600E and XIAP expression are commonly seen in PTC, their presence together seems unrelated." Gu and colleagues published their study in Thyroid (BRAF(V600E) Mutation and X-Linked Inhibitor of Apoptosis Expression in Papillary Thyroid Carcinoma. Thyroid, 2009;19(4):347-354). For additional information, contact Y.J. Zhao, Shanghai Jiao Tong University, Dept. of Endocrine & Metab Diseases, Rui Jin Hospital, Shanghai Institute Endocrine & Metab Diseases, School Medical, Shanghai Clinic Center Endocrine & Metab Diseases, 197 Rui Jin Er Rd., Shanghai 200025, People's Republic of China. Publisher contact information for the journal Thyroid is: Mary Ann Liebert Inc., 140 Huguenot Street, 3RD FL, New Rochelle, NY 10801, USA. Keywords: People's Republic of China, Shanghai, Apoptosis, Carcinogenesis, DNA, Diagnosis, Diagnostics, Enzyme Research, Hashimoto Thyroiditis, Nodular Goiter, Oncology, Papillary Thyroid Cancer, Polymerase, Thyroid Carcinoma, Thyroiditis, Shanghai Jiao Tong University. This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2009, Clinical Oncology Week via NewsRx.com.
|
